QuorumCivic. Hidden in plain sight Get the app
Bill intelligence
Full Simple

Bill delays Medicare price talks for brand-name biologic drugs two years.

S. 5571 — Biosimilars Access and Affordability Act · Filed by Marsha Blackburn (R-TN) · 3 cosponsors · Introduced Sep 28, 2026 · Referred to committee

25%
How clear the bill is
Typical bill: 85%
68/100
Chance of hidden extras
Typical bill: 15/100
High concernBiologic Drug Price Protection

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

The bill stops Medicare from negotiating prices on brand-name biologic drugs. This happens if a company says it is making a cheaper copy. The government waits up to two years after the announcement. If no cheaper copy comes to market within two years, price talks can start. The company that announced the copy must pay money back for the delay.

Who it affects

People on Medicare will pay higher prices for brand-name biologic drugs during the wait. The federal government will also pay more. Drug makers and companies working on cheaper copies are affected.

One thing to notice

A drug company can delay Medicare price talks by saying it plans to make a cheaper copy. If the cheaper copy never comes out, the brand-name drug maker gets two extra years of higher prices.

From the analysis of the bill text, linked under Primary records below.

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

  • Sep 28, 2026 — Introduced · Congress.gov: “Introduced in Senate”
  • Sep 28, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

9 groups reported lobbying about this bill. They filed 9 reports from Sep 2026 to Sep 2026.

Those reports show $14,555,000 in lobbying spending. Each report lists about 17 bills. So that money was not all for this bill.

More groups named this bill than 89% of bills with any report.

Marsha Blackburn, who sponsored the bill, received $135,620 from PACs for the 2026 election.

  • Pharmaceutical Research and Manufacturers of America — $7,040,000 in 1 report
  • Amgen Inc — $3,150,000 in 1 report
  • Biotechnology Innovation Organization — $2,560,000 in 1 report
  • Gsk (fka Glaxosmithkline Inc.) — $1,530,000 in 1 report
  • Alliance for Aging Research — $65,000 in 1 report

Lobbying is legal. These reports show who lobbied about this bill, not what changed.

Words to know

  • biologic drugs — Medicines made from living cells or organisms, not chemicals.
  • Medicare — The federal government's health insurance program for people age 65 and older.
  • lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
  • PACs — Groups that collect money and give it to candidates for office.
  • sponsored — To sponsor a bill is to introduce it in Congress and put your name on it.

How this was measured

Analysis — Quorum's AI read the bill text published by Congress.gov (11,354 characters) on Oct 6, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,684 analysed bills.

Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.

Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Sep 2026 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.

As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-16.

“Bill delays Medicare price talks for brand-name biologic drugs two years.” QuorumCivic. https://share.quorumcivic.app/bill/119/s5571/simple Report an error

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record

The week in bills

One email, Sunday: what Congress passed, what it changed, and who paid.

One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.